TIL Instil Bio, Inc.

NASDAQ
$7.17

Instil Bio, Inc. (TIL) is expected to report earnings on November 16, 2026, after the market close. The stock has had a Post-Earnings Announcement Drift (PEAD) of -1.8% since its last earnings release on August 13, 2026.

Instil Bio Reported Earnings
Thursday, August 13, 2026 · 5:00 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 5:00 PM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.35

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Instil Bio, Inc.

Instil Bio Inc. is a clinical-stage biopharmaceutical company. It is focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer. Instil Bio Inc. is based in DALLAS.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.